COGT vs. WVE, STOK, DNTH, CELC, CRBP, STTK, SLDB, ACRV, MACK, and IMMP
Should you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Wave Life Sciences (WVE), Stoke Therapeutics (STOK), Dianthus Therapeutics (DNTH), Celcuity (CELC), Corbus Pharmaceuticals (CRBP), Shattuck Labs (STTK), Solid Biosciences (SLDB), Acrivon Therapeutics (ACRV), Merrimack Pharmaceuticals (MACK), and Immutep (IMMP). These companies are all part of the "medical" sector.
Cogent Biosciences (NASDAQ:COGT) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
Cogent Biosciences has a net margin of 0.00% compared to Wave Life Sciences' net margin of -50.76%. Wave Life Sciences' return on equity of 0.00% beat Cogent Biosciences' return on equity.
Wave Life Sciences has higher revenue and earnings than Cogent Biosciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.
89.7% of Wave Life Sciences shares are owned by institutional investors. 5.1% of Cogent Biosciences shares are owned by insiders. Comparatively, 31.1% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Wave Life Sciences received 73 more outperform votes than Cogent Biosciences when rated by MarketBeat users. However, 70.65% of users gave Cogent Biosciences an outperform vote while only 67.25% of users gave Wave Life Sciences an outperform vote.
Cogent Biosciences has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.12, indicating that its share price is 212% less volatile than the S&P 500.
Cogent Biosciences currently has a consensus target price of $13.67, indicating a potential upside of 127.40%. Wave Life Sciences has a consensus target price of $10.14, indicating a potential upside of 113.98%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Wave Life Sciences.
In the previous week, Wave Life Sciences had 3 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Wave Life Sciences and 3 mentions for Cogent Biosciences. Wave Life Sciences' average media sentiment score of 0.39 beat Cogent Biosciences' score of 0.30 indicating that Wave Life Sciences is being referred to more favorably in the news media.
Summary
Wave Life Sciences beats Cogent Biosciences on 10 of the 15 factors compared between the two stocks.
Get Cogent Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cogent Biosciences Competitors List
Related Companies and Tools
